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Background: High-risk human papillomavirus (hrHPV)-positive women require triage to identify those with cervical high-grade
intraepithelial neoplasia and cancer (XCIN3 (cervical intraepithelial neoplasia grade 3)). FAM19A4 methylation analysis, which detects
advanced CIN and cancer, is applicable to different sample types. However, studies comparing the performance of FAM19A4methylation
analysis in hrHPV-positive self-samples and paired physician-taken scrapes are lacking.
Methods: We compared the performance of FAM19A4 methylation analysis (and/or HPV16/18 genotyping) in self-samples and paired
physician-taken scrapes for XCIN3 detection in hrHPV-positive women (n¼ 450,18–66 years).
Results: Overall FAM19A4 methylation levels between sample types were significantly correlated, with strongest correlation in women
with XCIN3 (Spearman’s r 0.697, Po0.001). The performance of FAM19A4 methylation analysis and/or HPV16/18 genotyping did not
differ significantly between sample types. In women X30 years, XCIN3 sensitivity of FAM19A4 methylation analysis was 78.4% in self-
samples and 88.2% in scrapes (ratio 0.89; CI: 0.75–1.05). In women o30 years, XCIN3 sensitivities were 37.5% and 45.8%, respectively
(ratio 0.82; CI: 0.55–1.21). In both groups, XCIN3 specificity of FAM19A4 methylation analysis was significantly higher in self-samples
compared with scrapes.
Conclusions: FAM19A4 methylation analysis in hrHPV-positive self-samples had a slightly lower sensitivity and a higher specificity for
XCIN3 compared with paired physician-taken scrapes. With a similarly good clinical performance in both sample types, combined
FAM19A4 methylation analysis and HPV16/18 genotyping provides a feasible triage strategy for hrHPV-positive women, with direct
applicability on self-samples.
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Epidemiological studies have established that a persistent infection
with a high-risk type of the human papillomavirus (hrHPV) is a
necessary aetiological factor for cervical cancer. Several randomised
trials have demonstrated that testing for the presence of hrHPV is a
more sensitive screening tool compared with cytology, providing
improved detection of cervical intraepithelial neoplasia grade 3
(CIN3) and cervical cancer (Dillner, 2013; Ronco et al, 2014).
However, the majority of hrHPV infections is transient, and only
upon accumulation of genetic and epigenetic changes in the host
and/or viral genomes, progression towards invasive cancer may
occur (Snijders et al, 2006; Steenbergen et al, 2014). To avoid
unnecessary referral to the gynaecologist of women with transient
hrHPV infections, identification of women with lesions reflecting
clinically relevant infections with a high risk of progression
towards cancer is required. Currently, cytology is the most
advocated triage tool for this purpose (Zorzi et al, 2013; Dijkstra
et al, 2014). However, cytology triage requires repeat testing to
ensure sufficient sensitivity (Rijkaart et al, 2012; Dijkstra et al,
2014) and has a subjective test result (Dijkstra et al, 2014).
Moreover, prior knowledge of the hrHPV status influences
cytology reading, resulting in an easier classification of abnormal
cytology, thus increasing the number of false-positives (Moriarty
et al, 2014). Although HPV16/18 genotyping might be a valuable
addition to cytology by eliminating the necessity of a repeat test
(Cox et al, 2013; Dijkstra et al, 2014), this combination may suffer
from non-detection of (pre)cancers associated with non-HPV16/18
hrHPV types.
As gene silencing by promoter hypermethylation has been
shown to contribute to cervical carcinogenesis, methylation
analysis of cancer-specific genes has been suggested as a valuable,
alternative or additive triage tool (Steenbergen et al, 2004;
Overmeer et al, 2009; Wilting et al, 2010; Saavedra et al, 2012).
Furthermore, in contrast to cytology, DNA methylation analysis
detects virtually all cervical carcinomas and is assumed to detect
‘advanced’ CIN lesions, that is, lesions with a long duration of
existence and with many chromosomal aberrations, which have a
high risk of short-term progression to cancer (De Strooper et al,
2014; Steenbergen et al, 2014). Gene promoter methylation can be
easily accessed by sensitive, quantitative methylation-specific PCR
(qMSP) providing an objective test outcome. Previous results in
hrHPV-positive cervical scrapes have been promising (Huang et al,
2010; Hesselink et al, 2011, 2014; Eijsink et al, 2012; Verhoef et al,
2014a), with sensitivities for CIN3 and cervical cancer (XCIN3)
equalling those of cytology analysis (Hesselink et al, 2011; Verhoef
et al, 2014a).
An important development in cervical cancer screening is the
use of self-collected cervicovaginal samples for women who do not
attend screening (Ogilvie et al, 2005; Snijders et al, 2013; Arbyn
et al, 2014). However, as cytology cannot be reliably performed on
self-sampled material (Nobbenhuis et al, 2002; Garcia et al, 2003),
triage of hrHPV-positive women by cytology still requires a visit to
a physician. In contrast, methylation analysis can be performed
directly on the self-collected sample (Eijsink et al, 2011; Hesselink
et al, 2014; Verhoef et al, 2014a). Indeed, a prospective trial in non-
responders has shown that detection of high-grade CIN with direct
MAL/miR124-2 methylation analysis on hrHPV-positive lavage-
collected self-samples is non-inferior to cytology triage on hrHPV-
positive physician-taken scrapes, thereby preventing diagnostic
delay and loss to follow-up (Verhoef et al, 2014a). Recently,
methylation analysis of the FAM19A4 gene has been shown to
yield attractive XCIN3 sensitivities and specificities in both
hrHPV-positive brush-collected and lavage-collected self-samples
(De Strooper et al, 2016) supporting the concept that it serves as a
universal triage test for HPV-positive cervicovaginal self-samples
collected by different self-collection devices.
Studies evaluating the concordance of methylation analysis
between self-collected cervicovaginal samples and physician-taken
cervical scrapes are however limited (Boers et al, 2014; Chang et al,
2015). Such evaluations are crucial to reveal the relative clinical
performance forXCIN3 detection compared with physician-taken
scrapes, as has been assessed for HPV testing (Arbyn et al, 2014).
It is well known that each sample type has its own cellular
composition with likely a different fraction of indicator cells
exfoliated from XCIN3, which may affect the performance of
molecular reflex tests. The present study compared the clinical
performance of FAM19A4 methylation analysis with and without
additional HPV16/18 genotyping, for the detection ofXCIN3 in a
unique cohort of paired self-collected cervicovaginal lavage
samples and physician-taken cervical scrapes of hrHPV-positive
women.
MATERIALS AND METHODS
Study design, participants and procedures. The present study
was conducted as a post hoc analysis of data obtained in a
prospective observational multicentre cohort study (COMETH),
which aimed to compare different triage strategies in hrHPV-
positive women (Luttmer et al, 2016). From December 2010 till
December 2013, women (age 18–70 years) who visited a
gynaecological outpatient clinic in one of six hospitals in the
Netherlands were asked to participate in the study. Women could
participate in the study regardless of their reason for referral to the
gynaecology outpatient clinic. After providing informed consent,
participants collected cervicovaginal lavage material (using the
Delphi screener; Delphi Bioscience, Scherpenzeel, The Nether-
lands) for hrHPV testing. Women who met the inclusion criteria
and tested hrHPV-positive on the cervicovaginal lavage were
invited for a cervical scrape and colposcopy. The cervical scrape
was taken by a physician using a Cervex-Brush (Rovers Medical
Devices BV, Oss, The Netherlands) or a Medscand Cytobrush Plus
(CooperSurgical Inc., Trumbull, CT, USA). Scrape material was
stored in 20ml of Thinprep PreservCyt solution (Hologic,
Marlborough, MA, USA) and was evaluated by FAM19A4
methylation analysis and HPV16/18 genotyping (cytology results
on these scrapes have been reported previously; Luttmer et al,
2016)). The study was approved by the Medical Ethical Committee
of all participating hospitals (METc-VUmc2009/178) and regis-
tered as NTR2447. Women with a history of treatment for cervical
dysplasia or cervical cancer, current cancer, pregnancy or lactation
were excluded from participation (Luttmer et al, 2016).
For logistic reasons, from 141 (31.3%) women, cervicovaginal
lavage material was collected by the physician before cervical
scraping using a Delphi screener according to the protocol. The
remaining 309 (68.7%) women self-collected lavage material at
home. In 268 (59.5%) women, the cervical scrape was taken at a
minimum of 2 weeks before colposcopy. In 182 (40.4%) women,
for logistic reasons, the cervical scrape was taken immediately
before colposcopy during the same visit to the gynaecologist.
As shown in Figure 1, in all women who tested both hrHPV-
positive on the cervicovaginal lavage and the cervical scrape
(n¼ 532), FAM19A4 methylation analysis was performed on each
sample type. All of these women had colposcopy-directed biopsy.
Women with invalid test results for FAM19A4 methylation
analysis of the cervicovaginal lavage (n¼ 48; 9.0%) or cervical
scrape (n¼ 43; 8.0%) were excluded from analyses. Of these,
nine women had an invalid test result in both the lavage and
scrape samples. The remaining women comprised the final study
population (n¼ 450).
Virtually all women (65 of 66; 98.4%) with histologically
confirmed CIN3 and adenocarcinoma in situ (AIS) in the biopsy
specimen were treated by large loop excision of the transformation
zone (LLETZ) or cervical conisation; one woman was followed up
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without treatment. Depending on the size of the lesion, also 55 of
85 (64.7%) women with a CIN2 biopsy underwent LLETZ. Of
these women, eight (14.5%) were diagnosed with CIN3 in the
LLETZ tissue, and categorised accordingly. In addition, one
woman with a CIN0 in the biopsy specimen had a CIN3 in the
tissue, which was obtained by (diagnostic) LLETZ.
Histological endpoints. In concordance with earlier work
(Luttmer et al, 2016), we used histologically confirmed XCIN3
as primary study end point and XCIN2 as a secondary study end
point. Unless otherwise specified, histological end points were
based on the histological outcome of the colposcopy-directed
biopsy, or, if classified worse, on the histology result of the
specimen excised by LLETZ, conisation or hysterectomy. In
addition, we attempted to provide a rough estimation of the
volume of CIN lesions. Therefore, histology results of biopsy
specimens and those of the corresponding LLETZ (or conisation/
hysterectomy) specimens are presented (Table 1). The presence of
XCIN3 in the LLETZ (or conisation/hysterectomy) specimen,
irrespective of the histological result of the biopsy, was considered
indicative of a high-volume XCIN3 lesion. The presence of CIN3
in the biopsy specimen, combined withpCIN2 in the correspond-
ing LLETZ specimen, was assumed to represent a low-volume
CIN3 lesion. Similarly, the presence of CIN2 in the LLETZ
specimen combined with pCIN2 in the corresponding biopsy
specimen was considered to indicate a high-volume CIN2 lesion.
The presence of CIN2 in the biopsy with pCIN1 in the LLETZ
specimen was assumed to represent a low-volume CIN2 lesion. In
women who were diagnosed with high-grade CIN on the biopsy
specimen and who did not receive LLETZ (according to physician’s
advice), lesions were classified as low volume.
HPV genotyping. DNA was isolated from one-fifth of cervicova-
ginal lavage specimens and one-tenth of cervical scrape material
using the Nucleo-Mag 96 Tissue Kit (Macherey-Nagel, Du¨ren,
Germany) and a Microlab Star robotic system (Hamilton,
Planegg, Germany) according to the manufacturer’s instructions
(Hesselink et al, 2011). Isolated DNA was subjected to GP5þ /6þ
PCR-enzyme immunoassay analysis (EIA Kit HPV GP HR;
Diassay BV, Rijswijk, The Netherlands) (Jacobs et al, 1997).
Subsequent genotyping for the high-risk HPV types 16/18/31/33/
35/39/45/51/52/56/58/59/66/68 was performed using a micro-
sphere bead-based assay (Luminex xMAP, Luminex Corp, Austin,
TX, USA) as described previously (Schmitt et al, 2006).
hrHPV-positive on lavage and
hrHPV-positive on scrape
n = 532
Lavage and scrape tested
for FAM19A4 methylation
Colposcopy-directed biopsy
n = 450
Final analysis
Exclusion from analyses                                        n = 82 (15%)
- Lavage: FAM19A4 methylation analysis invalid  n = 48   (9%)
- Scrape: FAM19A4 methylation analysis invalid  n = 43   (8%)
Histological endpoints*
No dysplasia (CIN0)
CIN1
CIN2
CIN3 (including AIS)
Squamous cell carcinoma
Adenocarcinoma
Histological endpoints*
No dysplasia (CIN0)
CIN1
CIN2
CIN3
Squamous cell carcinoma
Adenocarcinoma
n =   8 (22%)
n = 24 (29%)
n = 17 (21%)
n = 23 (8%)
n =   0 (0%)
n =   0 (0%)
Total group n = 450
n = 173 (38%)
n = 124 (28%)
n =   78 (18%)
n =   73 (16%)
n =    1 (0.2%)
n =    1 (0.2%)
<30 years n = 198
   n = 84 (42%)
   n = 55 (28%)
   n = 35 (18%)
   n = 24 (12%)
   n =   0   (0%)
   n =   0   (0%)
30 years n = 252
n = 89 (35%)
n = 69 (27%)
n = 43 (17%)
n = 49 (20%)
n =   1 (0.4%)
n =   1 (0.4%)
Figure 1. Overview of the study population and histological endpoints. *Histological endpoints were based on the histological outcome of the
colposcopy-directed biopsy, or, if classified worse, on the histology result of the specimen excised by LLETZ, conisation or hysterectomy.
AIS¼ adenocarcinoma in situ; CIN¼ cervical intraepithelial neoplasia; hrHPV¼high-risk human papillomavirus.
Table 1. Histology results of biopsy specimens and
corresponding LLETZ specimens
Histology LLETZ
(or conisation or hysterectomy)
Histology biopsy XCIN3 CIN2 pCIN1 No LLETZ
XCIN3 37a* 17b 11b 1b
CIN2 8a 25c 22d 30d
pCIN1 1a 1c 3e 294e
Abbreviations: CIN¼ cervical intraepithelial neoplasia; LLETZ¼ large loop excision of the
transformation zone.
aHigh-volume XCIN3 lesion (*including two carcinomas).
bLow-volume CIN3 lesion.
cHigh-volume CIN2 lesion.
dLow-volume CIN2 lesion.
epCIN1.
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qMSP analysis. Extracted DNA from hrHPV-positive cervicova-
ginal lavage specimens and cervical scrapes was treated with
bisulphite using the EZ DNA Methylation Kit (Zymo Research,
Irvine, CA, USA) as described previously (Overmeer et al, 2008,
2009). Bisulphite-converted DNA was used as template for
FAM19A4 methylation analysis by qMSP using housekeeping
gene b-actin (ACTB) as a reference (Steenbergen et al, 2013;
De Strooper et al, 2014). Quantitative methylation-specific PCR
analysis was carried out using an ABI 7500 Real-Time PCR-System
(Applied Biosystems, Waltham, MA, USA). For each target,
quantification cycle (Cq) values were measured at a fixed
fluorescence threshold. To assure sample quality, all samples
included in the study had a Cq value for ACTB o30. In case of
poor DNA concentration and an invalid test result, DNA isolation,
bisulphite treatment and qMSP were repeated with double sample
input if sufficient material was available for analysis. Cq ratios were
calculated for each sample using the following formula:
2(Cq (ACTB)Cq (FAM19A4)) 100. For both cervicovaginal lavage
specimens and cervical scrapes, assay thresholds, which gave rise to
a XCIN3 specificity of 70% using a training-validation set
approach (De Strooper et al, 2014), were chosen to consider a
specimen positive for FAM19A4 methylation.
Statistical analysis. The sample size was set such that 90% power
was achieved for demonstrating non-inferiority of FAM19A4
methylation analysis in cervicovaginal lavages to FAM19A4
methylation analysis in cervical scrapes using a matched-sample
score test (Tang et al, 2003; Meijer et al, 2009). A minimum of 300
hrHPV-positive women needed to be included at rejection rate a of
0.05. Finally, 450 hrHPV-positive women were included with
results for all markers.
For assessing overall genotype concordance, results were either
scored as concordant (sample types yielded completely identical
genotype results), compatible (one or more of the same genotypes
were detected) or discordant (no genotype similarities detected).
Paired evaluation of FAM19A4 Cq ratios in cervicovaginal lavages
and in cervical scrapes was carried out by Spearman’s rank
analysis.
The relation of the classification combining histological severity
and lesion volume with the percentage of FAM19A4 methylation-
positive and/or HPV16/18-positive samples was assessed using
Fisher’s exact test.
For both cervicovaginal lavages and cervical scrapes, clinical
performance of FAM19A4 methylation analysis and the combined
use of FAM19A4 methylation analysis and HPV16/18 genotyping
was evaluated. Clinical performance indicators were sensitivity,
specificity, positive predictive value (PPV) and complemented
NPV (1-negative predictive value, a measure of disease risk after a
negative result) for XCIN3 and XCIN2, and referral rate (based
on % marker positivity) were calculated. To enable comparisons,
relative sensitivity (ratio of the sensitivity of a marker in one
sample type to its sensitivity in the other sample type) and relative
specificity (ratio of the specificity of a marker in one sample type to
its specificity in the other sample type) were calculated with
95% CIs. If the 95% CI of the relative sensitivity or specificity
was entirely below or above one, the difference in sensitivity
or specificity was considered statistically significant. In case of
non-significant differences in sensitivity or specificity, an addi-
tional test was performed to evaluate non-inferiority. Non-
inferiority was defined as a relative sensitivity or specificity of at
least 90% using a matched-sample score test (Tang et al, 2003;
Meijer et al, 2009).
Using logistic regression, we analysed the influence of several
factors on the sensitivity and specificity of FAM19A4 methylation
analysis in this study population: the age of the participants (o30
years and X30 years), the reason for referral to the gynaecologist
(abnormal cytology result or other, non-cervix-related,
gynaecological complaints), the sampling method of the cervi-
covaginal lavage (collected by the participant at home or by the
physician) and the sampling moment of the cervical scrape (during
a separate visit 2–3 weeks before colposcopy or combined with the
colposcopy procedure). After finding a factor that significantly
influenced the performance of the different markers, data were
stratified for this factor. P-values o0.05 were considered
statistically significant. All statistical analyses and computations
of graphs were performed in IBM SPSS Statistics 20 (IBM
Corporation, Armonk, NY, USA), STATA 11.0 (StataCorp
LP, College Station, TX, USA) and Excel.
RESULTS
Study population. The study flowchart and histological end
points are shown in Figure 1. The final analysis comprised 450
women (age 18–66 years) who tested hrHPV-positive on both the
cervicovaginal lavage material and the cervical scrape, had valid
results for FAM19A4 methylation in both sample types and a
histological end point. FAM19A4 methylation scored positive in
26.4% (119 of 450) of the cervicovaginal lavage specimens and in
35.8% (161 of 450) of the cervical scrape specimens. Human
papillomavirus16 and/or HPV18 was present in 46.4% (209 of 450)
of the cervicovaginal lavage specimens and 47.3% (213 of 450) of
the cervical scrape specimens. Two women (0.4%) had invasive
cervical carcinoma (i.e., one squamous cell carcinoma (SCC) and
one adenocarcinoma), 73 women (16.2%) had CIN3 (including
one AIS), 78 women (17.3%) had CIN2, 124 (27.6%) had CIN1 and
173 (38.4%) had no CIN. In Table 1, histological results of biopsy
specimens and corresponding LLETZ results are presented.
Concordance of HPV genotypes and FAM19A4 methylation
analysis. Genotype agreement between the cervical scrape and
cervicovaginal lavage was concordant (sample types yielded
completely identical genotype results) in 60.7% (273 of 450) and
compatible (one or more of the same genotypes were detected) in
28.9% (130 of 450) of cases. In the remaining cases (47 of 450;
10.4%), genotypes were discordant between both sample types. As
shown in Table 2, for the majority of hrHPV types, genotype
concordance between cervical scrapes and cervicovaginal lavages
was substantial to almost perfect (Landis and Koch, 1977), both in
the total group and in the strata of histological severity. FAM19A4
Cq ratios in lavage samples were significantly correlated to those in
cervical scrapes in the total study population (Spearman’s r 0.394,
Po0.001). In the strata of histological severity, this correlation was
found to be strongest in women withXCIN3 (Spearman’s r 0.697,
Po0.001), followed by CIN2 (Spearman’s r 0.255, P¼ 0.024) and
pCIN1 (Spearman’s r 0.257, Po0.001). The correlation between
methylation Cq ratio in cervical scrapes and lavage samples in the
strata of histological severity is presented in Supplementary
Figure 1. Both women diagnosed with cervical cancer tested
positive for FAM19A4 methylation analysis in both sample types.
The woman with an adenocarcinoma tested HPV16-positive,
whereas the woman with an SCC harboured HPV39.
Performance of FAM19A4 methylation analysis in total study
population. Test specifications of FAM19A4 methylation analysis
in cervical scrapes (which were described previously; Luttmer et al,
2016) and in cervicovaginal lavages for detection of XCIN3 and
XCIN2 in the total study population are shown in Table 3 (upper
panel). Although the sensitivity of FAM19A4 methylation analysis
for the detection of XCIN3 was lower in cervicovaginal lavage
material (65.3%) compared with that in cervical scrapes (74.7%),
this difference was not statistically significant (ratio 0.88; CI: 0.75–
1.02). However, statistical non-inferiority (of lavages relative to
scrapes) could not be demonstrated (P¼ 0.64). The XCIN3
specificity of FAM19A4 methylation analysis was significantly
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higher in cervicovaginal lavages (81.3%) compared with that in
cervical scrapes (72.0%; ratio 1.13; CI: 1.05–1.21). For XCIN2
outcome in the total study population (Table 3; upper panel),
FAM19A4 methylation analysis had a significantly lower sensitivity
in cervicovaginal lavages (44.4%) compared with that in cervical
scrapes (56.9%), whereas its specificity in lavages (82.8%) was
significantly higher compared with that in scrapes (75.1%; relative
specificity 1.10; CI: 1.03–1.18).
Factors influencing the performance of FAM19A4 methylation
analysis: age. The performance of FAM19A4 methylation analysis
was significantly influenced by the age of the participants in both
sample types (Supplementary Tables 1A and B). Neither the reason
for referral of the participant (abnormal cytology result or other,
non-cervix-related, gynaecologic complaints) nor the sampling
method of the lavage (self-collected by the participant at home or
physician-collected) or scrape (during a separate visit 2–3 weeks
before colposcopy or combined with the colposcopy procedure)
influenced the performance of FAM19A4 methylation analysis
significantly (Supplementary Tables 1A and B). Given the
influence of age, the performance of FAM19A4 methylation
analysis was assessed in subgroups of women 18–30 years (referred
to as o30years) and women 30–66 years (referred to as X30
years). Sensitivity, specificity, PPV and complemented NPV of
FAM19A4 methylation analysis in both sample types and in both
age strata are shown in Table 3.
Table 2. HPV genotype concordance in cervical scrapes and cervicovaginal lavages
Scrapes Lavages
HPV genotype Positive na
Percentage
(%)a Positive na
Percentage
(%)a
Discordant
pairs nb
Concordance
total group j
XCIN3
j
XCIN2
j
pCIN1
j
HPV16 175 39 175 39 38 0.822 0.871 0.856 0.789
HPV31 58 13 64 14 32 0.697 0.721 0.655 0.717
HPV56 56 12 51 11 27 0.714 0.654 0.542 0.755
HPV18 52 12 52 12 22 0.761 0.802 0.762 0.760
HPV51 51 11 50 11 19 0.788 0.793 0.843 0.766
HPV66 49 11 64 14 19 0.808 0.517 0.802 0.811
HPV52 46 10 48 11 28 0.667 0.686 0.694 0.653
HPV45 41 9 41 9 24 0.678 0.737 0.765 0.642
HPV59 35 8 38 8 23 0.657 0.661 0.564 0.685
HPV58 25 6 25 6 20 0.576 0.551 0.719 0.490
HPV33 23 5 28 6 11 0.771 0.661 0.759 0.775
HPV35 21 5 31 7 18 0.633 0.786 0.745 0.559
HPV39 20 4 14 3 10 0.695 0.793 0.601 0.753
Abbreviations: CIN¼ cervical intraepithelial neoplasia; hrHPV¼high-risk human papillomavirus; k¼ kappa.
aFrequencies and percentages indicated here include the presence of types both in single and multiple infections; total n¼ 450 hrHPV-positive women; HPV68 was excluded owing to low
frequency (positive n¼ 4 in scrapes and n¼ 2 in lavages).
bNumber of discordant samples between scrape and lavage per single HPV type.
Table 3. Test specifications of FAM19A4 methylation analysis in cervical scrapes and cervicovaginal lavages for detection of
XCIN3 and XCIN2
Triage marker n1/N1
Sensitivity
(95% CI) n2/N2
Specificity
(95% CI)
PPV
(95% CI)
1-NPV
(95% CI)
Referral
rate (%)
Total group (n¼450)
XCIN3 FAM19A4 methylation scrape 56/75 74.7% (64.8–84.5) 270/375 72.0% (67.5–76.5) 34.8% (27.4–42.1) 6.6% (3.7–9.4) 35.8
FAM19A4 methylation lavage 49/75 65.3%a (54.6–76.1) 305/375 81.3%b (77.4–85.3) 41.2% (32.3–50.0) 7.9% (5.0–10.8) 26.4
XCIN2 FAM19A4 methylation scrape 87/153 56.9% (49.0–64.7) 223/297 75.1% (70.2–80.0) 54.0% (46.3–61.7) 22.8% (18.0–27.7) 35.8
FAM19A4 methylation lavage 68/153 44.4%b (36.6–52.3) 246/297 82.8%b (78.5–87.1) 57.1% (48.3–66.0) 25.7% (21.0–30.4) 26.4
Subgroup: women X30 years (n¼252)
XCIN3 FAM19A4 methylation scrape 45/51 88.2% (79.4–97.1) 127/201 63.2% (56.5–69.9) 37.8% (29.1–46.5) 4.5% (1.0–8.0) 47.2
FAM19A4 methylation lavage 40/51 78.4%a (67.1–89.7) 147/201 73.1%b (67.0–79.3) 42.6% (32.6–52.5) 7.0% (3.0–10.9) 37.3
XCIN2 FAM19A4 methylation scrape 66/94 70.2% (61.0–79.5) 105/158 66.5% (59.1–73.8) 55.5% (46.5–64.4) 21.1% (14.1–28.0) 47.2
FAM19A4 methylation lavage 55/94 58.5%b (48.6–68.5) 119/158 75.3%b (68.6–82.0) 58.5% (48.6–68.5) 24.7% (18.0–31.4) 37.3
Subgroup: women o30 years (n¼198)
XCIN3 FAM19A4 methylation scrape 11/24 45.8% (25.9–65.8) 143/174 82.2% (76.5–87.9) 26.2% (12.9–39.5) 8.3% (4.0–12.7) 21.2
FAM19A4 methylation lavage 9/24 37.5%a (18.1–56.9) 158/174 90.8%b (86.5–95.1) 36.0% (17.2–54.8) 8.7% (4.5–12.9) 12.6
XCIN2 FAM19A4 methylation scrape 21/59 35.6% (23.4–47.8) 118/139 84.9% (78.9–90.8) 50.0% (34.9–65.1) 24.4% (17.6–31.1) 21.2
FAM19A4 methylation lavage 13/59 22.0%b (11.5–32.6) 127/139 91.4%c (86.7–96.0) 52.0% (32.4–71.6) 26.6% (20.0–33.2) 12.6
Abbreviations: CI¼ confidence interval; CIN¼ cervical intraepithelial neoplasia (grade 2 or 3 or higher); HPV¼ human papillomavirus; n1¼ number of test positive disease cases; N1¼ total
number of disease cases; n2¼ number of test negative non-disease cases; N2¼ total number of non-disease cases; 1-NPV¼ complemented negative predictive value; PPV¼positive predictive
value.
aNo significant difference with FAM19A4 methylation in cervical scrape (in the corresponding category); non-inferiority test not significant.
bSignificant difference with FAM19A4 methylation in cervical scrape (in the corresponding category).
cNon-inferior to FAM19A4 methylation in cervical scrape (in the corresponding category).
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In women X30 years of age (n¼ 252), 51 XCIN3, 43 CIN2
and 158 pCIN1 were present (Table 3; middle panel). In this
sub-population, the sensitivity of FAM19A4 methylation analysis
for XCIN3 was lower in cervicovaginal lavages (78.4%) compared
with that in cervical scrapes (88.2%). Although this difference was
not statistically significant (ratio 0.89; CI: 0.75–1.05), statistical
non-inferiority could not be demonstrated (P¼ 0.56). The
specificity of FAM19A4 methylation analysis for XCIN3 was
significantly higher in lavages (73.1%) compared with that in
scrapes (63.2%; ratio 1.16; CI: 1.03–1.30). For detection ofXCIN2
in women aged X30 years, the sensitivity of FAM19A4 methyla-
tion analysis in lavages (58.5%) was lower compared with that in
scrapes (70.2%; ratio 0.83; CI: 0.70–0.999), and its specificity in
lavages (75.3%) was higher compared with that in scrapes (66.5%;
ratio 1.13; CI: 1.01–1.28).
In the subgroup of women o30 years of age (n¼ 198), 24
XCIN3, 35 CIN2 and 139 pCIN1 were present (Table 3, lower
panel). The sensitivity of FAM19A4 methylation analysis for
XCIN3 in lavages did not differ significantly from its sensitivity in
scrapes (37.5% vs 45.8%; ratio 0.82; CI: 0.55–1.21), but statistical
non-inferiority could not be established (P¼ 0.69). The specificity
of FAM19A4 methylation analysis for XCIN3 in lavages (90.8%)
was significantly higher compared with that in scrapes (82.2%;
ratio 1.10; CI: 1.02–1.20). The sensitivity of FAM19A4 methylation
for XCIN2 in lavages was significantly lower in lavages (22.0%)
compared with that in scrapes (35.6%; ratio 0.62; CI: 0.40–0.96),
whereas the XCIN2 specificity of this marker in lavages (91.4%)
was non-inferior to its specificity in scrapes (84.9%; ratio 1.08; CI:
0.99–1.17; non-inferiority test: P¼ 0.01).
The performance of FAM19A4 methylation analysis combined
with HPV16/18 genotyping. Table 4 presents the clinical
performance of FAM19A4 methylation analysis combined with
HPV16/18 genotyping for XCIN3 and XCIN2 in both sample
types. Compared with FAM19A4 methylation analysis alone
(Table 3), the combined marker panel (Table 4) reached
significantly higher XCIN3 and XCIN2 sensitivities, at signifi-
cantly lower specificities in both sample types and in both age
categories. In contrast to FAM19A4 methylation analysis alone, the
performance of combined FAM19A4 methylation analysis and
HPV16/18 genotyping did not differ significantly between
cervicovaginal lavages and cervical scrapes (Table 4).
FAM19A4 methylation analysis in relation to histological
severity. In an attempt to evaluate FAM19A4 methylation analysis
in relation to lesion severity and volume, participants were
stratified on the basis of a combination of histological severity
and volume of the CIN lesion (Table 1). FAM19A4 methylation
positivity rates in cervicovaginal lavages and cervical scrapes, in
relation to this combined classification, are presented in Table 5. In
both cervicovaginal lavage samples and cervical scrapes, the
percentage of FAM19A4 methylation-positive cases increased with
the lesion severity and volume (Po0.001 for both sample types;
Table 5). A similar increase in positivity rate was observed when
combining FAM19A4 methylation analysis and HPV16/18 geno-
typing, yet at overall higher positivity rates for each volume
category (Table 5).
DISCUSSION
This study compared the performance of FAM19A4 methylation
analysis in large series of paired self-collected cervicovaginal lavage
samples and physician-taken cervical scrapes for the detection of
Table 4. Test specifications of FAM19A4 methylation analysis combined with HPV16/18 genotyping in cervical scrapes and
cervicovaginal lavages for detection of XCIN3 and XCIN2
Triage marker n1/N1
Sensitivity
(95% CI) n2/N2
Specificity
(95% CI)
PPV
(95% CI)
1-NPV
(95% CI)
Referral
rate (%)
Total group (n¼450)
XCIN3 FAM19A4 methylation and/or
HPV16/18 genotyping scrape
69/75 92.0% (85.9–98.1) 165/375 44.0% (39.0–49.0) 24.7% (19.7–29.8) 3.5% (0.8–6.3) 62.0
FAM19A4 methylation and/or
HPV16/18 genotyping lavage
67/75 89.3%a (82.3–96.3) 181/375 48.3%a (43.2–53.3) 25.7% (20.4–31.0) 4.2% (1.4–7.1) 58.0
XCIN2 FAM19A4 methylation and/or
HPV16/18 genotyping scrape
117/153 76.5% (69.7–83.2) 135/297 45.5% (39.8–51.1) 41.9% (36.1–47.7%) 21.1% (14.9–27.2) 62.0
FAM19A4 methylation and/or
HPV16/18 genotyping lavage
110/153 71.9%b (64.8–79.0) 146/297 49.2%a (43.5–54.8) 42.1% (36.2–48.1) 22.8% (16.8–28.7) 58.0
Subgroup: women X30 years (n¼252)
XCIN3 FAM19A4 methylation and/or
HPV16/18 genotyping scrape
48/51 94.1% (87.7–100.0) 77/201 38.3% (31.6–45.0) 27.9% (21.2–34.6) 3.8% (0.0–7.9) 68.3
FAM19A4 methylation and/or
HPV16/18 genotyping lavage
47/51 92.2%b (84.8–99.5) 88/201 43.8%a (36.9–50.6) 29.4% (22.3–36.4) 4.3% (0.2–8.5) 63.5
XCIN2 FAM19A4 methylation and/or
HPV16/18 genotyping scrape
77/94 81.9% (74.1–89.7) 63/158 39.9% (32.2–47.5) 44.8% (37.3–52.2) 21.3% (12.3–30.2) 68.3
FAM19A4 methylation and/or
HPV16/18 genotyping lavage
73/94 77.7%b (69.2–86.1) 71/158 44.9%b (37.2–52.7) 45.6% (37.9–53.3) 22.8% (14.2–31.4) 63.5
Subgroup: women o30 years (n¼198)
XCIN3 FAM19A4 methylation and/
or HPV16/18 genotyping scrape
21/24 87.5% (74.3–100.0) 88/174 50.6% (43.1–58.0) 19.6% (12.1–27.2) 3.3% (0.0–7.0%) 54.0
FAM19A4 methylation and/or
HPV16/18 genotyping lavage
20/24 83.3%b (68.4–98.2) 93/174 53.4%b (46.0–60.9) 19.8% (12.0–27.6%) 4.1% (0.2–8.1) 51.0
XCIN2 FAM19A4 methylation and/or
HPV16/18 genotyping scrape
40/59 67.8% (55.9–79.7) 72/139 51.8% (43.5–60.1) 37.4% (28.2–46.6) 20.9% (12.5–29.2) 54.0
FAM19A4 methylation and/or
HPV16/18 genotyping lavage
37/59 62.7%b (50.4–75.1) 75/139 54.0%b (45.7–62.2) 36.6% (27.2–46.0%) 22.7% (14.3–31.0) 51.0
Abbreviations: CI¼ confidence interval; CIN¼ cervical intraepithelial neoplasia (grade 2 or 3 or higher); HPV¼ human papillomavirus; n1¼ number of test positive disease cases; N1¼ total
number of disease cases; n2¼ number of test negative non-disease cases; N2¼ total number of non-disease cases; 1-NPV¼ complemented negative predictive value; PPV¼positive predictive
value.
aNon-inferior to FAM19A4 methylation and/or HPV16/18 genotyping in cervical scrape (in the corresponding category).
bNo significant difference with FAM19A4 methylation and/or HPV16/18 genotyping in cervical scrape (in the corresponding category); non-inferiority test not significant.
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XCIN3 in hrHPV-positive women from a gynaecologic outpatient
population. FAM19A4 methylation analysis on self-collected lavage
material had a slightly lower sensitivity and a significantly higher
specificity compared with FAM19A4 methylation analysis on
physician-taken scrapes.
This study is the first large prospective multicentre cohort study
comparing the performance of methylation marker analysis in
hrHPV-positive cervicovaginal lavage samples to cervical scrapes
from the same women. The required number of participants with
and withoutXCIN3 lesions in this study was calculated in advance
to allow comparison of sensitivity and specificity in both sample
types. Until now, limited data comparing methylation marker
performance in paired samples were available. The methylation
markers studied by Boers et al (2014) (C13ORF18, EPB41L3, JAM3
and TERT) (Boers et al, 2014) and Chang et al (2015) (PAX1, SOX1
and ZNF582) have shown moderate to good concordance in self-
samples and cervical scrapes, yet these studies were performed on
very small study populations with limited controls and require
confirmation from other prospective studies.
In the current study, the differences in clinical performance
between the two sample types can most likely be attributed to a
different cellular composition and proportion of hypermethyla-
tion-positive cervical indicator cells. During cervical scrape
collection, a physician will target the transformation zone of the
cervix, contributing to a likely large number of cervical indicator
cells. In case of self-collection by a lavage device, a more random
distribution of vaginal and cervical indicator cells can be expected.
Consequently, the lower fraction of hypermethylated indicator cells
in self-collected lavages might explain the slightly lower sensitivity
and higher specificity of FAM19A4 methylation analysis.
Our previous studies have shown that FAM19A4 methylation
analysis and cytology on HPV-positive cervical scrapes have a
similar XCIN3 sensitivity (De Strooper et al, 2014; Luttmer et al,
2016). However, FAM19A4 methylation analysis has proven to be
more sensitive for the detection of CIN3 lesions with a longer
duration of existence (the so-called advanced lesions) and cervical
carcinoma (Luttmer et al, 2016). An advantage of the present study
is the availability of both biopsy and LLETZ histological results
from all participants with a high-grade lesion enabling a
semiquantitative assessment of lesion volume. We showed that in
both hrHPV-positive cervicovaginal lavages and cervical scrapes,
FAM19A4 methylation-positivity increases with the volume
of high-grade CIN lesions. These results support the concept
that FAM19A4 methylation analysis has a preference for detecting
the larger, probably more advanced CIN lesions (De Strooper et al,
2014). Of note, combined FAM19A4 methylation analysis and
HPV16/18 genotyping detected all but one high-volume XCIN3
lesions in both cervical scrapes and cervicovaginal lavages.
As expected, and found previously (Verhoef et al, 2014b; De
Strooper et al, 2016), the addition of HPV16/18 genotyping to
FAM19A4 methylation analysis yielded a significant increase
in sensitivity at the cost of a marked decrease in specificity.
Of interest, whereas FAM19A4 methylation analysis alone was
found to be slightly less sensitive and more specific in the
cervicovaginal lavages compared with the cervical scrapes, no
significant differences were found for the marker combining
FAM19A4 methylation analysis and HPV16/18 genotyping. Thus,
the combination of FAM19A4 methylation analysis with HPV16/
18 genotyping might be a safe alternative triage strategy that
performs similarly on both sample types.
In line with earlier studies (Luttmer et al, 2016), our data
showed a significant influence of age on FAM19A4 methylation
positivity in both cervical scrapes and cervicovaginal lavage
material. Accordingly, in young women, FAM19A4 methylation
analysis results in quite low XCIN2/3 sensitivities of only 37.5–
45.8%, at relatively high specificities of 82.2–90.0%. In young
women, hrHPV prevalence is known to be high, but the majority of
infections are transient and most lesions, also a substantial part of
CIN3 lesions, tend to regress spontaneously (Winer et al, 2003;
Insinga et al, 2010; Jaisamrarn et al, 2013), contributing to a very
low cancer incidence in this age category (Benard et al, 2012). As
FAM19A4 methylation analysis has previously shown to preferably
detect advanced CIN lesions and cervical cancer (De Strooper et al,
2014; Steenbergen et al, 2014), this lower sensitivity has the clinical
benefit that it could protect young women from overtreatment.
This is particularly relevant for women in their reproductive age as
treatment may lead to adverse pregnancy outcome.
Owing to the selection of an outpatient population, the
translation of our results into screening settings should be handled
with care. Further confirmation in population-based screening
trials is required as the percentage of HPV-positive women with
XCIN3 lesions in a screening population is lower compared with
that in a gynaecologic referral population. Another limitation of
our study is the relatively large number of samples with an invalid
test result for FAM19A4 methylation analysis of 8% in the cervical
scrapes and 9% in the cervicovaginal lavage samples. These invalid
test results on the cervical scrapes might result from cautious
scraping during colposcopy to prevent bleeding and thus poor
Table 5. FAM19A4 methylation results in cervicovaginal lavages and cervical scrapes in relation to histological results of the
biopsy and LLETZ specimen
FAM19A4 methylation analysis
FAM19A4 methylation analysis and/or
HPV16/18 genotyping
Lavage Scrape Lavage Scrape
Histology and lesion
volume
Positive n/
total n Percentage
Positive n/
total n Percentage
Positive n/
total n Percentage
Positive n/
total n Percentage
High-volume XCIN3a 35/46 76.1 41/46 89.1 45/46 97.8% 45/46 97.8
Low-volume CIN3b 14/29 48.3 15/29 51.7 22/29 75.9 24/29 82.8
High-volume CIN2c 8/26 30.8 12/26 46.2 15/26 57.7 17/26 65.4
Low-volume CIN2d 11/52 21.2 19/52 36.5 28/52 53.8 31/52 59.6
pCIN1e 51/297 17.2 74/297 24.9 151/297 50.8 162/297 54.5
Abbreviations: CIN¼ cervical intraepithelial neoplasia; HPV¼human papillomavirus; LLETZ¼ large loop excision of the transformation zone. Fisher’s exact test Po0.001 for both FAM19A4
methylation analysis and the combination of FAM19A4 methylation analysis and HPV16/18 genotyping, in both lavages and scrapes.
aLLETZ (or conisation/hysterectomy) specimen XCIN3 (including two carcinomas).
bBiopsy specimen CIN3, LLETZ specimen pCIN2.
cBiopsy specimen pCIN2, LLETZ specimen CIN2.
dBiopsy specimen CIN2, LLETZ specimen pCIN1.
eBoth biopsy specimen and LLETZ specimen (if available) pCIN1.
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visualisation, leading to low DNA concentrations (Overmeer et al,
2011). Indeed, 88.4% of the invalid results were found in scrapes
that were collected directly before colposcopy, a procedure that is
not likely to be applied in a routine cervical screening setting.
Also in self-samples, the number of cells can be limited or the
sample can be of poor quality, for example, by collection or storage
failures. This problem can be circumvented by using a larger
fraction of the scrape or self-sample in the DNA isolation
procedure, or by decreasing the elution volume during isolation.
Given the study setting aiming to evaluate different triage
strategies, leftover sample material was not always sufficient to
perform repeat methylation analysis. In routine setting, this
limitation will likely not be applicable, as also supported by the
limited occurrence of methylation-invalid samples in a randomised
controlled trial in screening setting (Verhoef et al, 2014a).
In conclusion, FAM19A4 methylation marker analysis in
hrHPV-positive self-collected lavage samples had a slightly lower
sensitivity and a higher specificity for XCIN3 compared with
FAM19A4 methylation analysis in paired physician-taken scrapes.
Combined FAM19A4 methylation analysis and HPV16/18 geno-
typing revealed a similarly good clinical performance, which was
similar in both sample types. Therefore, this combination could
provide a feasible triage strategy for hrHPV-positive women, with
the advantage of direct applicability on self-collected material.
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